Renal cell carcinoma

Adjuvant therapy in RCC

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Освітня мета: To assess the recurrence risk after nephrectomy and appropriately select patients who are at high risk of renal cell carcinoma (RCC) recurrence and may benefit from adjuvant treatment.
Спеціальність: Urology, Medical oncology, Clinical oncology
Цільова аудиторія: Specialists (CME: basic, intermediate), Residents (senior)
Останнє оновлення: January 2025
Фон:

Regulatory approval status of drugs mentioned in this CME course, restricted to the adjuvant treatment setting (status 22 January 2025)

This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.